Purpose: Delayed ferumoxytol enhancement on T1-weighted images appears visually similar to gadoteridol enhancement. The purpose of this study was to quantitatively compare ferumoxytol T1 enhancement to gadoteridol enhancement with an objective, semi-automated method. Methods: 206 sets of post-gadoteridol and 24h post-ferumoxytol T1-weighted scans from 58 high grade glioma patients were analyzed (9 pre-chemoradiation, 111<90 days post-chemoradiation, 21>90 days post-chemoradiation, 65 post-bevacizumab scans). Enhancement volumes and signal intensities normalized to normal appearing tissue proximal to enhancement were calculated with a semi-automated method. Enhancement cube root volumes (D) and signal intensities (SI) were compared between the 2 contrast agents, and relative difference of D and SI were compared in different treatment groups with multivariate analysis. Within patient differences in D and SI before and after treatment with bevacizumab or steroid were assessed in 26 patients in each treatment group. Results: When compared to gadoteridol, ferumoxytol D was 13.83% smaller and SI was 7.24% lower (P<0.0001). The relative differences in D and SI between the 2 contrast agents were not significantly different between treatment groups (P>0.05). Relative difference in D and SI did not change significantly in response to bevacizumab (P=0.5234 and P=0.2442, respectively) or to steroid (P=0.3774, P=0.0741) in the within patient comparison. Conclusion: The correlation between the 2 contrast agents' enhancement size and signal intensity and their similar behavior in response to therapy suggest that ferumoxytol can be used for revealing enhancement in high grade glioma patients.
- Alternative contrast agent
- Delayed enhancement
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging